Key Financial Figures
FY26 Performance:
- Revenue: ₹33,653 crores (6% YoY growth)
- EBITDA: ₹6,856 crores (4% YoY growth)
- EBITDA Margin: 20.4%
- Ex-gRevlimid revenue growth: 9.5% YoY
- Gross Contribution: ₹20,165 crores (60% margin, 100 bps improvement)
- R&D Expenditure: ₹1,590 crores (5% of revenue)
- Net CapEx: $341 million
- Net Cash Position: $317 million (up from $276 million in Dec'25)
Q4 FY26 Performance:
- Revenue: ₹8,853 crores
- EBITDA: ₹1,801 crores (20.3% margin)
- Net Profit: ₹921 crores (2% YoY growth)
- Ex-gRevlimid revenue growth: 15.3% YoY (7% in USD terms)
- Gross Contribution: ₹5,424 crores
- Gross Margin: 61.3% (153 bps QoQ improvement)
- R&D Expenditure: ₹400 crores
- Net CapEx: $82 million
- Average Finance Cost: 5%
Business Segment Performance
Formulations Business (86% of total revenue):
- Q4 Revenue: ₹7,646 crores (5% YoY growth)
API Business (14% of total revenue):
- Q4 Revenue: ₹1,208 crores (25% QoQ growth)
- FY26 Revenue: ₹4,047 crores (12% of total)
Geographic Performance:
- US Formulations: Q4 revenue decreased 18% YoY to $387 million (constant currency), primarily due to high gRevlimid sales in Q4 FY25. Full year revenue was $1,631 million.
- Europe Formulations: Q4 revenue ₹2,795 crores (30% YoY growth), €261 million vs €236 million in Q4 FY25. Achieved €1 billion annual revenue milestone.
- Growth Markets: Q4 revenue ₹980 crores (25% YoY, 13% QoQ growth). Full year revenue ₹3,499 crores (10% growth).
- ARV Business: Q4 revenue ₹328 crores ($36 million, 6% YoY growth). Full year revenue ₹1,384 crores ($157 million, 33% growth).
- Specialty & Injectable: Q4 global revenue $122 million. Ex-gRevlimid, business grew 13% YoY. Full year revenue $513 million, ex-gRevlimid growth 12%.
Operational Highlights
Pen-G and 6-APA Facilities:
- Achieved positive EBITDA contribution in Q4 FY26
- Annualized production expected to exceed 10,000 metric tons with >80% capacity utilization
- External sales exceeded ₹100 crores in Q4
- FY26 EBITDA loss of approximately ₹200+ crores for Pen-G/6-APA
China Facility:
- Expected to achieve profitable EBITDA contribution in FY27
Biosimilars Business:
- Total investment of ~$450 million to date
- Current portfolio includes 4 European approvals, 2 Health Canada approvals
- Planned 2026 US filings for Omalizumab, Denosumab, and Bevacizumab
- Targeting 7-8 products in Europe/growth markets and 2-3 products in US by 2030
- Expected gross margins of 65%-75% in US market
Biologics CMO (TheraNym):
- Unit 1 (60 KL capacity) commissioning by end-2026
- Validation batches scheduled in 2027, revenue expected from 2028
- Unit 2 (greenfield) commissioning expected in 2029, revenue from 2031
- Three product schedules signed with MSD for commercial biological entities
- Total planned capacity: 120,000 litres mammalian cell culture
- Investment: ~$175 million for greenfield facility
Acquisitions and Expansion:
- Lannett acquisition expected to close in Q2 FY27 (delayed due to 76-day US government shutdown affecting FTC)
- Khandelwal Laboratories non-oncology acquisition completed ($32 million consideration)
- China-OSD facility scaling up with increasing approvals for European markets
FY27 Outlook
- EBITDA margins expected to sustain and progressively improve to north of 21%
- US business targeting $2 billion revenue milestone (includes Lannett contribution)
- Europe business targeting double-digit growth in constant currency terms
- Domestic formulation business expected to grow in double digits
- China facility targeting low double-digit EBITDA margin
- Pen-G/6-APA expected to maintain positive EBITDA contribution
Other Key Information
- Working capital improvement contributed to strong cash flow generation
- Power and fuel costs increased significantly in Q4 due to Pen-G plant operations
- 1% INR depreciation against USD translates to ~₹100 crores EBITDA impact
- Eugia Unit III and Unit I awaiting EIR (Establishment Inspection Report)
- Ryzneuta launch delayed; building scientific story in competitive market
- ADQUEY (eczema drug) launch targeted for Q2 FY27